Affiliation:
1. Group of Biotechnology and Bacterial Infections, Department of Microbiology, Cali, Colombia
2. Department of Nutrition and Dietetics, IU Escuela Nacional del Deporte, Cali, Colombia
3. Department of Surgery, Division of Urology/Uro-Oncology, School of Medicine, Universidad del Valle, Cali, Colombia
Abstract
Goals:
To evaluate the efficacy and safety of standard triple therapy (STT) in Latin America.
Background:
Helicobacter pylori infection affects more than 50% of the Latin Americans and leads to gastric mucosa damage. Scarce data on effective therapeutic approaches in the region underscores the need for comprehensive information.
Study:
The analysis included Randomized Controlled Trials published up to the year 2020, comparing STT with other treatments. Cumulative relative risks (RR) were estimated, with 95% CI, according to intention-to-treat (ITT) and per protocol (PP) analysis.
Results:
Eleven studies (clinical trials conducted between 1995 and 2013), revealed cumulative eradication rates of 78.31–90.63% (ITT) and 76.71–93.55% (PP). The eradication with the STT was superior to sequential therapy (ITT—RR: 10.6, 95% CI: 1.01 to 1.12) (PP—RR: 10.6, 95% CI: 1.02-1.11) and dual therapy (ITT—RR: 1.61, 95% CI: 1.13-2.30) (PP—RR: 1.72, 95% CI: 1.25-2.37), but is less effective than other triple therapies (PP—RR: 0.85, 95% CI: 0.78-092). Regarding adverse effects, diarrhea, metallic taste, nausea, vomiting, and headache were the most common symptoms across treatments. Abdominal pain was associated with STT (ITT—RR: 1.75, 95% CI: 1.07-2.86).
Conclusion:
STT was a safe regimen but with acceptable efficacy (most eradication rates <90%). Due to rising clarithromycin resistance, the study suggests avoiding STT as a first-line treatment. These results must be considered with caution due to the low representativeness of several Latin American countries and the lack of recent high-quality randomized studies.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Reference44 articles.
1. Clinical management of Helicobacter pylori: the Latin American perspective;Coelho;Dig Dis,2014
2. Helicobacter pylori therapy: a paradigm shift;Graham;Expert Rev Anti-infective Ther,2016
3. Helicobacter pylori related health problems in children;Akcam;Iran J Public Health,2015
4. World gastroenterology organisation global guideline: Helicobacter pylori in developing countries;Hunt;J Gastrointestin Liver Dis,2011
5. The effect of antibiotic resistance on Helicobacter pylori eradication efficacy: a systematic review and meta-analysis;Zou;Helicobacter,2020